InvestSMART

Orthocell Limited (ASX: OCC) - Share Price

- Current share price for OCC : $0.765

Orthocell Limited (OCC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a regenerative medicine company engaged in developing products for the repair of bone and soft tissue injuries. The company has appointed a network of specialist distributors in the United States and recorded initial sales. The company's nerve repair product holds approval in Australia, New Zealand and Singapore and is distributed through Device Technologies Group in those markets.

OCC General Information +

ASX Code OCC
Website http://www.orthocell.com.au
Industry/Sector Biotechnology
Market Cap ($M) 208
OCC Share Price $0.765
Day High $0.780
Day Low $0.765
Last Close $0.765
OCC Share Price Movement - ( No change )
Prices as at 16:40, 17 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Orthocell Limited (OCC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Orthocell Limited (OCC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Orthocell Limited (OCC) price-sensitive announcements

OCC - Q4 FY26 ASX Investor Presentation
Orthocell Limited's Q4 FY26 ASX Investor Presentation highlights a strong quarter with sig
Orthocell Limited (OCC)
14 Jul 2026 | 8:47 AM
OCC - Quarterly Activity Report & Appendix 4C
Orthocell Limited has reported a strong quarterly performance for the period ending 30 Jun
Orthocell Limited (OCC)
13 Jul 2026 | 8:53 AM
OCC - Orthocell Appoints Thailand Distributor for Remplir
Orthocell Limited, a regenerative medicine company, announced the appointment of MediTime
Orthocell Limited (OCC)
3 Jul 2026 | 8:56 AM
OCC - First Sales of Remplir Achieved in US$75m Canadian Market
Orthocell Limited has achieved its first commercial sales of the nerve repair device Rempl
Orthocell Limited (OCC)
30 Apr 2026 | 9:14 AM

Orthocell Limited (OCC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Orthocell Canaccord Genuity Conference Live Webcast 12 Aug 2026 8:27AM $0.800 $0.765 fallen by 4.38%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Orthocell to Present at Canaccord Growth Conference 11 Aug 2026 8:45AM $0.730 $0.765 risen by 4.79%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Change of Registered Office & Principal Place of Business 3 Aug 2026 8:38AM $0.730 $0.765 risen by 4.79%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Appendix 3Y - John Van Der Wielen 20 Jul 2026 6:10PM $0.720 $0.765 risen by 6.25%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Application for quotation of securities - OCC 20 Jul 2026 6:06PM $0.720 $0.765 risen by 6.25%
Orthocell Limited (OCC)
ORDINARY FULLY PAID
 Health Care $208 Appendix 3Y x 4 17 Jul 2026 4:42PM $0.725 $0.765 risen by 5.52%

OCC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$2.00 -50.00% 0.00 0.00 0.00% 0.0%
2026F C2 -$4.00 4.20% 0.00 0.00 0.00% 0.0%
2025A -$8.57 -$3.80 8.20% 0.00 0.00 0.00% 0.0%

OCC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
CSL Limited (CSL) $65,371M 0.1108 -0.1247 0.0167 14.6370 16.7226 16.4484 3.27% 2.66% 2.76%
Clinuvel Pharmaceuticals Limited (CUV) $482M 0.0287 0.0000 0.0000 13.3008 0.0000 0.0000 0.52% 0.00% 0.00%
Mesoblast Limited (MSB) $2,870M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Orthocell Limited (OCC) $210M 0.0817 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,685M -1.3893 0.0000 -0.1438 0.0000 276.5289 322.9730 0.00% 0.00% 0.00%

OCC Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 12.80 0.00
Market 0.30 13.10 1.16 0.67
Sector 0.51 33.10 2.42 2.70

OCC Directors

Name Position Start Date
Mr Paul Frederick Anderson Chief Executive Officer, Managing Director 21 Mar 2006
Dr Ravi Thadhani Lead Independent Director, Non-Executive Director 8 Mar 2023
Mr John Van Der Wielen Non-Executive Chairman, Non-Executive Director 1 Jun 2023
Professor Fiona Melanie Wood Non-Executive Director 1 Nov 2023
Mr Michael McNulty Non-Executive Director 1 Sep 2025

Orthocell Limited (OCC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
20 Jul 2026 WIELEN, John Issued Direct Shares 15,430 $0.756 $11,666.670
17 Jul 2026 WOOD, Fiona Issued Indirect Shares 11,573 $0.756 $8,750.000
17 Jul 2026 MCNULTY, Michael Issued Indirect Shares 11,573 $0.756 $8,750.000

See all changes in directors' interest & trades for Orthocell Limited (OCC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

OCC Management

Name Position
Peter Webse Company Secretary

OCC Calendar of Events

Date Event
23 February 2027 Report (Interim)
02 October 2026 Report (Annual)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.